Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Alterity Therapeutics (NASDAQ: ATHE) announced participation in two upcoming virtual investor events. CEO David Stamler will speak at the MST Financial Lifesciences & Biotech Forum on November 24, 2021, at 5:20 p.m. PST, and the Benchmark Company Discovery Conference on December 2, 2021. These events aim to highlight Alterity's innovative treatments for neurodegenerative diseases, particularly their lead asset, ATH434, targeting Parkinsonian disorders. For further details, visit www.alteritytherapeutics.com.

MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events:

MST Financial Lifesciences & Biotech Fourm
Wednesday, November 24^th at 5:20 p.m. PST (U.S.) / Thursday, November 25^th at 12.20 pm AEST
A link to the live and recorded webcast will be available on the Alterity website.

Benchmark Company Discovery One-on-One Investor Conference
Thursday, December 2^nd (U.S.) /  Friday, December 3^rd (Australia)

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contact: Investor Relations

Australia	US
Rebecca Wilson	Remy Bernarda
E: WE-AUAlterity@we-worldwide.com	remy.bernarda@iradvisory.com
Tp: +61 417 382 391	Tp: +1 (415) 203-6386

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-two-upcoming-investor-conferences-301429828.html

SOURCE Alterity Therapeutics Limited

FAQ

What events is Alterity Therapeutics participating in this November 2021?

Alterity Therapeutics is participating in the MST Financial Lifesciences & Biotech Forum on November 24, 2021.

When will David Stamler speak at the MST Financial Lifesciences & Biotech Forum?

David Stamler will speak at the MST Financial Lifesciences & Biotech Forum on November 24, 2021, at 5:20 p.m. PST.

What is the focus of Alterity Therapeutics?

Alterity Therapeutics focuses on developing disease-modifying treatments for neurodegenerative conditions.

When is the Benchmark Company Discovery Conference that Alterity will attend?

The Benchmark Company Discovery One-on-One Investor Conference will take place on December 2, 2021.

What is the significance of ATH434 for Alterity Therapeutics?

ATH434 is Alterity's lead asset, which has the potential to treat various Parkinsonian disorders.